News
-
-
PRESS RELEASE
BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator
BRAIN Biotech AG concludes a major pharma compound transaction valued up to EUR 128.88 million, monetizing royalty rights with Royalty Pharma for investigational compound deucrictibant from BioIncubator -
PRESS RELEASE
EQS-Adhoc: BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma
BRAIN Biotech AG concludes royalty monetization deal for up to EUR 128.88 million on investigational pharma compound deucrictibant with Royalty Pharma -
-
-
-
-
-
-